Media Articles Related to Cevimeline
Source: MedicineNet Thyroid Peroxidase Test Specialty [2013.09.26]
Title: Sjogren's Syndrome
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 9/26/2013 12:00:00 AM
Published Studies Related to Cevimeline
Effectiveness of cevimeline to improve oral health in patients with postradiation
of life (QOL) in patients with xerostomia... CONCLUSIONS: Xerostomia is a significant sequela of treatment of head and neck
Comparison of the effects of pilocarpine and cevimeline on salivary flow. [2009.05]
OBJECTIVE: The aim of the present study was to compare the effect of low-dose pilocarpine and cevimeline as stimulants for salivary flow in healthy subjects... CONCLUSION: Both drugs showed efficacy in increasing the salivary flow in healthy volunteers, but cevimeline was more effective than pilocarpine.
Therapeutic effect of cevimeline on dry eye in patients with Sjogren's syndrome: a randomized, double-blind clinical study. [2004.07]
PURPOSE: Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by salivary and lacrimal glandular destruction leading to symptoms of dry mouth and dry eye. Dryness can also occur in the absence of glandular destruction. Patients with SS have autoantibodies that bind to muscarinic acetylcholine receptors in the exocrine glands. Recently, a muscarinic acetylcholine receptor agonist, cevimeline, has been approved for use against symptoms of dry mouth in patients with SS. In this study, the efficacy of cevimeline in improving symptoms of dry eye was examined. DESIGN: Prospective, randomized, double-blind, multi-center clinical study... CONCLUSIONS: These results indicate that cevimeline, 20 mg three times daily, is safe and effective in improving symptoms of dry eye in patients with SS. Additional studies, with larger patient populations, are needed to further assess the effectiveness of cevimeline for dry eye.
Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. [2002.06.10]
BACKGROUND: Cevimeline hydrochloride is a cholinergic agent with muscarinic agonist activity prominently affecting the M1 and M3 receptors prevalent in exocrine glands. We evaluated the safety and efficacy of cevimeline in the treatment of xerostomia in patients with Sjogren syndrome... CONCLUSIONS: Therapy with cevimeline, 30 mg 3 times daily, seems to be well tolerated and to provide substantive relief of xerostomia symptoms. Although both dosages of cevimeline provided symptomatic improvement, 60 mg 3 times daily was associated with an increase in the occurrence of adverse events, particularly gastrointestinal tract disorders. Use of 30 mg of cevimeline provides a new option for the treatment of xerostomia in Sjogren syndrome.
A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren's syndrome patients with xerostomia and keratoconjunctivitis sicca. [2002.03]
OBJECTIVE: To evaluate the safety and efficacy of 2 dosages of cevimeline for the treatment of xerostomia and keratoconjunctivitis sicca in patients with Sjogren's syndrome... CONCLUSION: Treatment with cevimeline at a dosage of 30 mg 3 times daily resulted in substantive improvement by increasing the rate of saliva and tear flow in patients with Sjogren's syndrome, as well as improving subjective symptoms of dry mouth, dry eyes, and overall dryness. The 15-mg dosage relieved some symptoms, and both dosages were well tolerated.
Clinical Trials Related to Cevimeline
Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia [Recruiting]
The purpose of this study is to determine the effectiveness of cevimeline (versus placebo)
on the oral health of patients who have dry mouth which was caused by radiation therapy that
was given for treatment of head and/or neck cancer.
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer [Completed]
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation
therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no
therapy in treating dry mouth caused by radiation therapy.
PURPOSE: Randomized phase III trial to determine the effectiveness of cevimeline in treating
patients who have dryness of the mouth caused by radiation therapy for head and neck cancer.